Objective measurement and clinical significance of TILs in non-small cell lung cancer.
about
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancerFocus on Nivolumab in NSCLCHeterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategiesPrognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.Classifying Cancers Based on T-cell Infiltration and PD-L1.A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial).Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer.PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer.The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survivalPrognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung CancerHHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survivalAnalysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis.Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.What does the future hold for immunotherapy in cancer?The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Diagnosis and Molecular Classification of Lung Cancer.Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy.Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter.Elevated Foxp3/CD8 Ratio in Lung Adenocarcinoma Metastatic Lymph Nodes Resected by Transcervical Extended Mediastinal LymphadenectomyQuantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.Tumor lymphocytic infiltration in non-small cell lung cancer: the ultimate prognostic marker?Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract CaPrognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer.Implications of the tumor immune microenvironment for staging and therapeutics.Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer.Role of immune-checkpoint inhibitors in lung cancer.
P2860
Q28072004-152D1119-8DB6-4EA5-98DA-0FE588EB3C54Q28073759-F252C85B-FD69-4CC4-92DB-0309D5B60452Q30275647-07E67D3B-1FA3-4915-8533-8F629137ED3BQ33728267-ADAF48AD-6D87-436F-99D8-DB53D6566BD5Q35674821-C05485AD-441D-4034-8F8C-D7307D67EA61Q35873571-AD8AF115-D31B-43E8-B5FA-E8D9C269ACB6Q35922142-0DFE5E93-988E-4127-B99A-AA71AE55C938Q35996819-93D94235-4455-4748-9BA9-9FE9736D6CBCQ36378871-7F7D05EE-7CF4-4870-BE02-BEC40D483B1CQ36772177-2951EF62-CA9F-4B0E-B328-62AE10E35EDBQ36829208-6E4D924E-3DE2-43FC-AD5D-AF5BACDAA40BQ36898444-6383832F-C307-4E08-A8A7-6565B07B28BFQ36915205-495811A7-F941-4578-87B2-CD72BE4EF8CAQ37087884-64DF6D78-EC61-48CE-B165-7E27101BE9F1Q37181493-BF054EAF-F78D-4A73-9234-BC50474AA2A7Q37619675-19D8AEEE-E94E-4ECC-8FEE-5E56E6C657A6Q37665660-1D5A904C-5E2E-4DA7-B1D8-F46F579A19A7Q38633171-EC7FBFDC-4D32-428D-BB1B-82B528F90DC7Q38636708-9B92A450-131D-4010-B055-01C1F694F340Q38856436-DE360346-68FA-4BF1-A427-179A46E28575Q38879975-2A8C7A8A-35DD-4D56-9CBA-9DF37DAF967FQ38930336-3BE3F899-30AA-4169-BB2C-1ABE737AAF4DQ38938285-8B6F4434-B22E-4FFF-A5DF-C48747CCA065Q38961444-C531DB8C-0CBE-4170-B5C5-17145FA8FB49Q40496586-E60EFF29-950A-42AA-ABC8-62679AD268B0Q40559745-8459671E-143F-4322-8B72-A7B7A880546FQ40610329-F5CA9D50-BC4A-4101-AA3D-247CBA9839ACQ41092061-EB7B0B66-E614-4C90-9134-F17E9E7D78D4Q41112503-9938B14C-008C-4E0C-A337-42572A861096Q41430954-9494C113-9B4E-4677-A0C7-B0B0345DAC3AQ42393214-0EEC9A7B-76DA-4924-A9A8-84FDA2AF9D34Q42398706-A2C61F4B-42FC-41A4-83F0-7C925523DE12Q46540302-77A8B5C1-50CB-423D-BD69-07F605D2D161Q47152515-F55FEBEA-3EA2-4921-9C24-649E9B2E1271Q47320798-675BFFD3-E660-4FFC-8C57-CE389D652633Q47332473-CD0B53D8-579C-4C2A-9F9D-93853DAB64E8Q47581436-B64B9252-E921-49E4-B4A8-7557216E2CB2Q47592007-8ED12058-F317-465D-88A5-505C2962357EQ48248023-5027621D-6A21-4982-819C-BE83D1781D97Q49549096-2429EC4E-97FD-4F7A-BBB6-EB80F3F091C7
P2860
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
@ast
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
@en
type
label
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
@ast
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
@en
prefLabel
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
@ast
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
@en
P2093
P2860
P356
P1476
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
@en
P2093
Daniel Carvajal-Hausdorf
David L Rimm
Jason Brown
Joseph McLaughlin
Konstantinos N Syrigos
Vamsidhar Velcheti
P2860
P356
10.1093/JNCI/DJU435
P407
P577
2015-02-03T00:00:00Z